To test iHet_rev more extensively, we considered different cohorts of patients treated with ICB for which both baseline RNA-seq and response data were available, and which have been previously used to test state-of-the-art predictors: patients with skin cutaneous melanoma (SKCM) treated with anti-PD-1 (30 non-responders and 20 responders),61,62 with bladder carcinoma (BLCA) treated with anti-PD-L1 (129 non-responders and 21 responders),63 or with stomach adenocarcinoma (STAD) treated with anti-PD-1 (33 non-responders and 12 responders).64 Here, PDCD1 is linked to urinary bladder carcinoma.